Counting days: Cardiovascular and kidney event postponement with glucagon‐like peptide 1 receptor agonists in individuals with type 2 diabetes
- 24 February 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (5) , 4372-4375
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or ObesityDiabetes Care, 2025
- The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic actionTrends in Cardiovascular Medicine, 2024
- The time‐varying cardiovascular benefits of glucagon‐like peptide‐1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trialsDiabetes, Obesity and Metabolism, 2022
- Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical TrialsJournal of General Internal Medicine, 2019